Alopecia Universalis
15
2
3
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
6.7%
1 terminated out of 15 trials
87.5%
+1.0% vs benchmark
20%
3 trials in Phase 3/4
71%
5 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Systemic Treatments for Alopecia Areata Registry
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
Clinical Application of Stem Cell Educator Therapy in Alopecia Areata
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata
Alopecia Areata Registry
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata